Research points to a key bone-strengthening mechanism at work in the body, which could be targeted to treat the bone-weakening disease, osteoporosis.
Led by scientists from the University of Leipzig in Germany and Shandong University in China, the 2025 study identified the cell receptor GPR133 (also known as ADGRD1) as being crucial to bone density, via bone-building cells called osteoblasts.
Variations in the GPR133 gene had previously been linked to bone density, leading researchers to turn their attention to the protein it encoded.







